Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.15
Bid: 4.00
Ask: 4.30
Change: 0.10 (2.47%)
Spread: 0.30 (7.50%)
Open: 4.05
High: 4.29
Low: 4.05
Prev. Close: 4.05
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Safestyle suffers amid "difficult" trading conditions

Wed, 27th Sep 2023 13:10

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Safestyle UK PLC - Bradford-based retailer and manufacturer of PVCu replacement windows and doors - Revenue in half-year ended July 2 declines 5.3% on-year to GBP74.1 million from GBP78.3 million. Pretax loss widens to GBP6.7 million from GBP2.8 million. Decides against interim dividend, after 0.4 pence per share payout a year prior. "The trading context of the UK economy and consumer confidence remains extremely difficult. Encouragingly, inflation is beginning to show some signs of moderating, but that follows a period of sustained high inflation. The impact of significantly higher interest rates than expected is clearly impacting consumers' disposable income," Safestyle says.

----------

Zegona Communications PLC - London-based company focused on communications and entertainment opportunities - Pretax loss in six months to June narrows slightly to EUR1.8 million from EUR1.9 million. Generates no revenue, unchanged year-on-year. Zegona adds: "Over the last 6 months we have continued to focus on identifying and pursuing the right opportunity within the European telecommunications market where we can again successfully apply our proven "buy-fix-sell" strategy to generate attractive returns for our shareholders. We remain patient and disciplined in our approach and are encouraged by the stabilisation in both the economic outlook and telecommunications market trends, which contribute to the confidence we have in our ability to find the right next investment for Zegona." On Friday, it confirmed it was in talks with Vodafone Group PLC to acquire its Spanish operations. Zegona said the deal remains subject to agreement on final terms with Vodafone, completion of its due diligence and formalisation of funding arrangements. As a result, it stressed that there is "no certainty" that the potential acquisition will go ahead, nor as to any of the final terms if a deal were to be struck.

----------

ProBiotix Health PLC - Wakefield, England-based life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions - Pretax loss in six months to June 30 widens to GBP512,000 from GBP251,000 a year prior. It reports "other administrative costs" more than double to GBP668,000 from GBP274,000. Revenue rises 83% to GBP552,000 from GBP302,000. Chief Executive Officer Steen Andersen says: "Since I took over as CEO in January 2023, my focus has been on building and developing a defined strategy whereby we are looking to become a solutions provider of finished probiotic products in consumer formats. My objective is to build ProBiotix into a GBP10 million plus turnover company, marketing our products both under our own brands and partner private labels. We are excited about the future of the company and remain committed to providing long term value to our shareholders."

----------

OptiBiotix Health PLC - York, England-based life sciences company, which develops edible compounds to tackle chronic conditions like obesity and diabetes - Swings to pretax loss of GBP1.9 million in first six months of 2023, from profit of GBP13.9 million a year prior. In the prior year, it booked a GBP21.6 million profit on the disposal of a subsidiary. It registers no such gains this time around. Revenue rises to GBP351,000 from GBP119,000. CEO Stephen O'Hara says: "The aim for the second half of the year is to maintain our focus on managing costs, growing sales and closing out ongoing discussions with a number of larger partners across first and second-generation products to ensure a return on investment from the expansion of our commercial and business development teams."

----------

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Revenue in year ended June 30 falls 16% to GBP61.0 million from GBP72.8 million. Allergy's pretax loss stretches to GBP49.8 million from GBP12.7 million. "This financial year has been challenging, however, the group has made good progress in recovering manufacturing capacity and developing robust quality systems that are well-placed to support future growth," CEO Manuel Llobet says.

----------

Fadel Partners Inc - media rights and royalty management software developer - Revenue in half-year ended June 30 declines 20% to USD5.4 million from USD6.7 million a year earlier. Pretax loss widens to USD1.3 million from USD1.1 million. CEO Tarek Fadel says: "The outlook for Fadel remains positive and the benefits of our investments are already coming through as the strong trading momentum enjoyed in 1H23 continues into the second half of the year. Investments made in the business to date, alongside the wider shift towards digitisation, are driving increased demand for our offering and give great confidence in the group's outlook."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 Nov 2023 12:33

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

Read more
16 Oct 2023 08:40

ZQ makes mandatory offer for Allergy Therapeutics as holding hits 60%

(Alliance News) - ZQ Capital Management Ltd on Monday announced a mandatory takeover offer for Allergy Therapeutics PLC, as required under UK takeover rules, but it said the offer won't be accepted by the Allergy's second largest shareholder and so won't succeed.

Read more
13 Oct 2023 14:07

IN BRIEF: Allergy Therapeutics raises GBP40.8 million in fundraise

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says that it has conditionally raised total gross proceeds of approximately GBP40.8 million through an equity financing, which was announced on April 6. Proceeds of the equity financing will be used to repay amounts owed under the loan facility agreement.

Read more
26 Sep 2023 19:38

TRADING UPDATES: Cohort trading ahead of expectations, record orders

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Sep 2023 20:37

TRADING UPDATES: Braemar investigation to end; Marula reports delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday, Thursday and Wednesday and not separately reported by Alliance News:

Read more
10 Aug 2023 11:11

Allergy Therapeutics shares plunge on expected loss and revenue drop

(Alliance News) - Allergy Therapeutics PLC on Thursday said it expects to swing to a loss for the full-year as revenue plummets on production disruptions.

Read more
10 Jul 2023 13:45

Allergy Therapeutics appoints new CFO; interim CFO to leave in August

(Alliance News) - Allergy Therapeutics PLC on Monday said it has promoted Group Financial Controller Shaun Furlong to chief financial officer.

Read more
19 Jun 2023 11:40

Allergy Therapeutics banks on second half-year to boost revenue

(Alliance News) - Allergy Therapeutics PLC on Monday said its loss widened and revenue fell, with costs going up as new research studies progress, but predicted improved sales in the second half of the year thanks to higher demand in the seasonal allergy market.

Read more
6 Apr 2023 14:42

Allergy Therapeutics enters GBP41 million facility with ZQ Capital

(Alliance News) - Allergy Therapeutics PLC on Thursday said it has entered into a senior secured facility agreement with ZQ Capital Management Ltd, through its affiliate SkyGem International Holdings Ltd and Southern Fox Investments Ltd.

Read more
27 Mar 2023 18:42

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 15:16

Allergy Therapeutics starts dosing peanut allergy vaccine candidate

(Sharecast News) - Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its 'VLP Peanut' vaccine candidate in peanut-allergic patients on Monday.

Read more
20 Jan 2023 12:33

Allergy Therapeutics confident in funding as results remain late

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said in an update on Friday that it expects first-half revenue of £39.9m, making for a decrease of 18% year-on-year.

Read more
20 Jan 2023 10:37

Allergy Therapeutics revenue drops but optimistic about funding

(Alliance News) - Allergy Therapeutics PLC on Friday said it expects a drop in revenue during the first half of its financial year, but it remains confident about funding opportunities.

Read more
29 Dec 2022 16:52

LONDON MARKET CLOSE: FTSE 100 edges higher and New York stocks jump

(Alliance News) - London's FTSE 100 achieved a solid, though unspectacular, gain during the final full trading of the year on Thursday, with investors mindful of what an ease of Covid-19 curbs in China could mean for global inflation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.